As reported by Drug Store News, toothpastes that aim to better deliver such value-added benefits as teeth whitening and relieving tooth sensitivity are resonating with consumers, so the lift in sales of such products comes as little surprise.
This may be the year of the legacy brands as two companies that recently acquired separate brand portfolios from GlaxoSmithKline focus on reinvigorating consumer attention to their respective product lines.
GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.
Prestige Brands closed out its fiscal 2012 ended March 31 on a high note with $441.1 million in revenues for the year, up 31.1%. And fiscal 2013 is looking promising as the company will have full-year contributions from its 17 acquired over-the-counter brands from GlaxoSmithKline.
Appropriately promoting niche brands within the intimacy health space can be a little trickier than the average consumer packaged goods product. And social media isn’t necessarily the ideal platform — an adult may not be as comfortable “liking” an intimacy enhancement product on Facebook to show their brand affinity, for example.
Steve Anderson recalled during Sunday morning’s State of the Association address how when he started as the president and CEO of the National Association of Chain Drug Stores five years ago, people were interested to see what his eyes would discover at NACDS and within community pharmacy that might help make a difference for the future. Anderson said that today he answers that question in the same way he did back then: “Every day my eyes see something fresh in what you do — in the innovative offerings of community pharmacy.”
Prestige Brands Holdings on Monday announced that it has completed the purchase of the two remaining brands of the 17 brands it agreed to acquire from GlaxoSmithKline; the purchase of Debrox ear wax remover and Gly-Oxide oral rinse completes the transaction.
Breast cancer patients taking an experimental drug made by Roche subsidiary Genentech lived significantly longer than those taking another drug made by GlaxoSmithKline, according to results of a late-stage clinical trial.